After Rite Aid (NYSE: RAD) released a fiscal second-quarter report Thursday morning showing sales and adjusted net income that were lower year over year, shares of the drugstore chain tumbled, and were off 11.2% at 12:30 p.m. EDT.
Continue Reading Below
Rite Aid spent a lot of time focusing on its now-failed merger plans with Walgreens Boots Alliance (NASDAQ: WBA), and according to management, that combined with pricing pressure to take a toll on its financial performance.
The company reported that its sales for the period, which ended Sept. 2, slipped 4.4% to $7.68 billion, and that after adjusting for one-time items, including a $325 million termination fee paid to it by Walgreens, it lost $0.01 per share. Last year, Rite Aid reported earnings of $0.03 per share in its Q2.
Rite Aid's poor performance was driven in part by lower prescription volume, which in turn, reduced front-of-store sales due to lower foot traffic. Same-store sales fell 3.4% year over year, with a 4.6% drop in pharmacy sales and a 0.9% decrease in front-end sales. Revenue from its pharmacy benefit manager unit, EnvisionRx, slipped as expected, but a better proportion of higher-margin clients kept its adjusted EBITDA flat.
Said Rite Aid Chairman and CEO John Standley:
After regulators blocked its planned merger with Walgreens, Rite Aid cut a deal to sell 1,932 stores and three distribution centers to its former suitor for $4.375 billion in cash. That deal got a regulatory green light, and is expected to be completed by early next year.
The sale should leave Rite Aid leaner, but financially healthier. It built up a mountain of debt via earlier acquisitions, which it plans to use proceeds from the divestiture to shrink. That in turn will lower its interest expenses, which last quarter eclipsed $220 million.
This sell-off could be viewed as an intriguing entry for risk-tolerant investors. Assuming that Rite Aid can rejuvenate its balance sheet and refocus on winning back customers, its weak results from this year should offer easier comparisons in 2018, and if margin improves thanks to lower interest expense, then profits should too.
10 stocks we like better than Rite AidWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Rite Aid wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.